Yang Ruoqi, Zha Xuan, Gao Xingyi, Wang Kangmin, Cheng Bin, Yan Bin
Shandong University of Traditional Chinese Medicine, Jinan, 250355, China.
Heliyon. 2022 Sep 1;8(9):e10495. doi: 10.1016/j.heliyon.2022.e10495. eCollection 2022 Sep.
p38α is a mitogen-activated protein kinase (MAPK), and the signaling pathways involved are closely related to the inflammation, apoptosis and differentiation of cells, which also makes it an attractive target for drug discovery. With the high efficiency and low cost, virtual screening technology is becoming an indispensable part of drug development. In this study, a novel multi-stage virtual screening method based on machine learning, molecular docking and molecular dynamics simulation was developed to identify p38α MAPK inhibitors from natural products in ZINC database, which improves the prediction accuracy by considering and utilizing both ligand and receptor information compared to any individual approach. Ultimately, we screened out two candidate inhibitors with acceptable ADMET properties (ZINC4260400 and ZINC8300300). Among the generated machine learning models, Random Forest (RF) and Support Vector Machine (SVM) performed better, with the area under the receiver operating characteristic curve (AUC) values of 0.932 and 0.931 on the test set, as well as 0.834 and 0.850 on the external validation set. In addition, the results of molecular docking and ADMET prediction showed that two compounds with appropriate pharmacokinetic properties had binding free energies less than -8.0 kcal/mol for the target protein, and the results of molecular dynamics simulations further confirmed that they were stable during the process of inhibition.
p38α是一种丝裂原活化蛋白激酶(MAPK),其涉及的信号通路与细胞的炎症、凋亡和分化密切相关,这也使其成为药物研发的一个有吸引力的靶点。虚拟筛选技术凭借其高效性和低成本,正成为药物开发中不可或缺的一部分。在本研究中,开发了一种基于机器学习、分子对接和分子动力学模拟的新型多阶段虚拟筛选方法,用于从ZINC数据库中的天然产物中识别p38α MAPK抑制剂,与任何单一方法相比,该方法通过考虑和利用配体和受体信息提高了预测准确性。最终,我们筛选出了两种具有可接受的药物代谢动力学性质的候选抑制剂(ZINC4260400和ZINC8300300)。在生成的机器学习模型中,随机森林(RF)和支持向量机(SVM)表现更好,在测试集上的受试者工作特征曲线(AUC)值分别为0.932和0.931,在外部验证集上分别为0.834和0.850。此外,分子对接和药物代谢动力学预测结果表明,两种具有适当药代动力学性质的化合物与靶蛋白的结合自由能小于-8.0 kcal/mol,分子动力学模拟结果进一步证实它们在抑制过程中是稳定的。